Antitumor activity of solamargine in mouse melanoma model: relevance to clinical safety

Author(s)

Furtado, Ricardo Andrade ^[1] ; Ozelin, Saulo Duarte ^[1] ; Ferreira, Natalia Helen ^[1] ; Miura, Barbara Ayumi ^[1] ; Almeida Junior, Silvio ^[1] ; Magalhaes, Georgia Mode ^[1] ; Nassar, Eduardo Jose ^[1] ; Miranda, Mariza Abreu ^[2] ; Bastos, Jairo Kenupp ^[2] ; Tavares, Denise Crispim ^[1]

Affiliation

^[1] Univ Franca, Ave Dr Armando Salles Oliveira, 201 Parque Univ, BR-14404600 Franca, SP - Brazil

^[2] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Sao Paulo, SP - Brazil

• Document type: Journal article
• Source: JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES; v. 85, n. 4 OCT 2021.
• Web of Science Citations: 0

Abstract

Melanoma is the most aggressive type of skin cancer, and thus it is important to develop new drugs for its treatment. The present study aimed to examine the antitumor effects of solamargine a major alkaloid heteroside present in Solanum lycocarpum fruit. In addition solamargine was incorporated into nanoparticles (NP) of yttrium vanadate functionalized with 3-chloropropyltrimethoxysilane (YVO4:Eu3+:CPTES:SM) to determine antitumor activity. The anti-melanoma assessment was performed using a syngeneic mouse melanoma model B16F10 cell line. In addition, systemic toxicity, nephrotoxic, and genotoxic parameters were assessed. Solamargine, at doses of 5 or 10 mg/kg/day administered subcutaneously to male C57BL/6 mice for 5 days, decreased tumor size and frequency of mitoses in tumor tissue, indicative of a decrease in cell proliferation. Treatments with YVO4:Eu3+:CPTES:SM significantly reduced the number of mitoses in tumor tissue, associated with no change in tumor size. There were no apparent signs of systemic toxicity, nephrotoxicity, and genotoxicity initiated by treatments either with solamargine alone or plant alkaloid incorporated into NP. The animals treated with YVO4:Eu3+:CPTES:SM exhibited significant increase in spleen weight accompanied by no apparent histological changes in all tissues examined. In addition, animals treated with solamargine (10 mg/kg/day) and YVO4:Eu3+:CPTES:SM demonstrated significant reduction in hepatic DNA damage which was induced by tumor growth. Therefore, data suggest that solamargine may be considered a promising candidate in cancer therapy with no apparent toxic effects. (AU)

• FAPESP's process: 13/02744-7 - Antitumoral and toxicological potential of solamargine functionalized with yttrium vanadate nanoparticles
• Grantee: Ricardo Andrade Furtado
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 13/13903-9 - Evaluation of genotoxic and antioxidant activities of Styrax camporum hydroalcoholic extract and their chemical markers, egonol and homoegonol, and their influence on genomic and pre-neoplasic lesions
• Grantee: Denise Crispim Tavares
• Support Opportunities: Regular Research Grants
• FAPESP's process: 19/02641-0 - 6th Nano Today Conference
• Grantee: Eduardo José Nassar
• Support Opportunities: Research Grants - Meeting - Abroad